open access

Vol 21, No 2 (2018)
Clinical vignette
Published online: 2018-06-11
Submitted: 2018-03-19
Accepted: 2018-04-24
Get Citation

Simultaneous breast cancer and DLBCL lymphoma — role of PET/CT examination with 18F-FDG and 18F-FES

Łukasz Hołody, Jolanta Kunikowska, Janusz Braziewicz
DOI: 10.5603/NMR.a2018.0020
·
Pubmed: 29956818
·
Nucl. Med. Rev 2018;21(2):113-114.

open access

Vol 21, No 2 (2018)
Clinical vignette
Published online: 2018-06-11
Submitted: 2018-03-19
Accepted: 2018-04-24

Abstract

Breast cancer is the most common cancer in women in the western world.

The estrogen receptor (ER) is expressed in two thirds of newly diagnosed breast cancers, so hormonal treatment is performed only in the receptor positive patients. The most successful ER imaging radiopharmaceutical in PET techniques is 16α-[18F]-flouro-17β-estradiol (18F-FES).

The diffuse large B cell lymphoma (DLBCL) is one of the most common NHL, however, non-Hodgkin lymphoma constitutes only 4% of all primary cancers in women. The typical staging of disease is done using 18-fluorodeoksyglukose (18F-FDG) PET/CT.

Abstract

Breast cancer is the most common cancer in women in the western world.

The estrogen receptor (ER) is expressed in two thirds of newly diagnosed breast cancers, so hormonal treatment is performed only in the receptor positive patients. The most successful ER imaging radiopharmaceutical in PET techniques is 16α-[18F]-flouro-17β-estradiol (18F-FES).

The diffuse large B cell lymphoma (DLBCL) is one of the most common NHL, however, non-Hodgkin lymphoma constitutes only 4% of all primary cancers in women. The typical staging of disease is done using 18-fluorodeoksyglukose (18F-FDG) PET/CT.

Get Citation

Keywords

PET/CT, FES, breast cancer

About this article
Title

Simultaneous breast cancer and DLBCL lymphoma — role of PET/CT examination with 18F-FDG and 18F-FES

Journal

Nuclear Medicine Review

Issue

Vol 21, No 2 (2018)

Pages

113-114

Published online

2018-06-11

DOI

10.5603/NMR.a2018.0020

Pubmed

29956818

Bibliographic record

Nucl. Med. Rev 2018;21(2):113-114.

Keywords

PET/CT
FES
breast cancer

Authors

Łukasz Hołody
Jolanta Kunikowska
Janusz Braziewicz

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl